Photo of Jeffrey Aeschlimann

Jeffrey Aeschlimann

  • E-Mail
  • Phone
    • (860) 679-1488 or (860) 486-3350
  • Fax
    • (860) 679-4871
  • Mail
    • University of Connecticut
      School of Pharmacy Room 346
      69 North Eagleville Road, Unit 3092
      Storrs, Connecticut 06269-3092
  • Practice Site
    • UConn Health Center
      Department of Pharmacy
      263 Farmington Avenue, MC2205
      Farmington, Connecticut 06030

Pharm.D.
Associate Professor of Pharmacy Practice


Educational Background

  • Post-doctoral Fellowship in Infectious Diseases Pharmacotherapy, Wayne State University, Detroit, MI, 1996-1998
  • Doctor of Pharmacy, University of Utah, Salt Lake City, UT, 1994-1996
  • B.S., Pharmacy, University of Connecticut, Storrs, CT, 1998-1993

Professional Interests

  • Quantification of the impact of multidrug efflux pump protein overproduction on antibiotic activity for Pseudomonas aeruginosa.
  • Study of the mechanism(s) of antibiotic resistance of bacterial biofilms and the impact of “classic” antibiotic resistance on biofilm formation.
  • Antibiotic pharmacodynamics for Gram-negative and Gram-Positive bacteria.
  • Investigations of novel antibiotic dosing strategies to prevent or overcome antibiotic resistance in both the clinical and laboratory settings.
  • Development and validation of novel in vitro systems that model human infections and predict in vivo antimicrobial activity.
  • Use of active learning/problem-based learning for the teaching of Infectious Diseases Therapeutics to Pharm.D. students.  Selected Professional Accomplishments

Selected Professional Accomplishments

  • Aeschlimann JR and Bryers JD. Bacterial Biofilms in Human Infections. American College of Clinical Pharmacy Infectious Diseases Practice & Research Network Minisabbatical Award
  • Aeschlimann JR. Risk Factors and Clinical Outcomes in Patients with Infections due to Pseudomonas aeruginosa that Overexpress Efflux Pumps. Society of Infectious Diseases Pharmacists Research Award.
  • Aeschlimann JR. The Effects of Vancomycin Crystalline Degradation Product 1 (CDP-1) on Selection of Vancomycin Resistance in Staphylococcus aureus. ACCP Aventis Infectious Diseases Research Award, University of Connecticut Faculty Large Grant Competition Award.
  • Aeschlimann JR. Comparative Pharmacodynamics of Levofloxacin 500 and 750 mg every 24 hours, Alone and in Combinations with Other Antipseudomonal Antibiotics, against Pseudomonas aeruginosa. Ortho-McNeil Pharmaceuticals.
  • Aeschlimann JR. Targeted Strategies to Prevent the Emergence of Ciprofloxacin-Resistant Pseudomonas aeruginosa. Bayer Pharmaceuticals.

Selected Publications

View Publications on PubMed »

Selected Presentations

  • Aeschlimann JR. “Vancomycin Crystalline Degradation Product Can Help Select and Maintain Staphylococcus aureus Strains with Reduced Susceptibility to Vancomycin.”  In: Program and Abstracts of the 2003 American College of Clinical Pharmacy Annual Meeting, Atlanta, GA., November 2-5, 2003.
  • Aeschlimann JR. “Risk Factors and Clinical Outcomes of Patients with Infections Caused by Efflux Pump Overproducing Pseudomonas aeruginosa.” Presented at: Society of Infectious Diseases Pharmacists Annual Meeting, Chicago, IL, 9/27/03.
  • Aeschlimann JR, Milliken S, Bryant D, Doyle CJ, and D’Souza NK. “Adaptive Resistance to Aminoglycosides is Lost upon Overproduction of MexXY-OprM or MexAB-OprM Efflux Pumps in Pseudomonas aeruginosa.” In: Programs & Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, Sept 14-17, 2003.
  • Aeschlimann JR, Doyle CJ, and D’Souza NK. “Antipseudomonal Activity and Resistance Prevention for Different Multidrug Efflux Pump (MDEP) Substrates Combined with Levofloxacin in an In Vitro Infection Model (IVIM).” In: Programs & Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, Sept 14-17, 2003.
  • Aeschlimann JR and D’Souza NK. “Comparative Antipseudomonal Activity of High-Dose Levofloxacin (L) and Ciprofloxacin (C) in an In Vitro High-Inoculum Infection Model.” In: Program and Abstracts of the 103rd General Meeting of the American Society for Microbiology, Washington, D.C., May 17-21, 2003.